Bridging cholinergic signalling and inflammation in schizophrenia.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Eugenol mitigates schizophrenia-like behavioral deficits, oxidative stress, apoptosis, neuroinflammation, and cholinergic dysfunction in ketamine-induced mice.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026
   Article
2. Association between metabolic syndrome, diabetes mellitus, inflammation and cognitive dysfunctions in schizophrenia: a cross-sectional analysis.Schizophrenia (Heidelberg, Germany) · 2025
   Article
3. Repurposing medications to prevent psychosis.Npj mental health research · 2025
   Review
4. Novel opportunities for treating complex neuropsychiatric and neurocognitive conditions based on recent developments with xanomeline.Frontiers in psychiatry · 2025
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

Abstract

PubMed holds no abstract for this paper.